Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
High density lipoprotein measurement
|
1440 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.800 | 1.000 | 2 | 2009 | 2012 | |||||
Coronary heart disease
|
1178 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.710 | 1.000 | 2 | 2011 | 2016 | |||||
Serum HDL cholesterol measurement
|
679 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.700 | 1.000 | 2 | 2009 | 2012 | |||||
Triglycerides measurement
|
1418 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.700 | 1.000 | 1 | 2018 | 2018 | |||||
Alzheimer's Disease
|
1843 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.020 | 1.000 | 2 | 2012 | 2013 | |||||
Amyotrophic Lateral Sclerosis
|
485 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Dyslipidemias
|
184 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Gallbladder Carcinoma
|
75 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.010 | 1 | 2013 | 2013 | ||||||
Hodgkin Disease
|
148 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Huntington Disease
|
115 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Ischemic stroke
|
704 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Malignant neoplasm of gallbladder
|
81 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.010 | 1 | 2013 | 2013 | ||||||
Multiple Sclerosis
|
1022 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Stage 0 Gallbladder Cancer AJCC v8
|
56 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.010 | 1 | 2013 | 2013 | ||||||
Stage IIA Gallbladder Cancer AJCC v8
|
56 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.010 | 1 | 2013 | 2013 | ||||||
Stage IIB Gallbladder Cancer AJCC v8
|
56 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.010 | 1 | 2013 | 2013 | ||||||
Stage III Gallbladder Cancer AJCC v8
|
56 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.010 | 1 | 2013 | 2013 | ||||||
Stage IV Gallbladder Cancer AJCC v8
|
56 | 0.716 | 0.360 | 11 | 47264739 | intron variant | T/C | snv | 0.38 | 0.010 | 1 | 2013 | 2013 |